These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8999195)

  • 1. [Cardioxan as a cardioprotector in antineoplastic chemotherapy].
    Lichinitser MP; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
    Klin Med (Mosk); 1996; 74(5):65-7. PubMed ID: 8999195
    [No Abstract]   [Full Text] [Related]  

  • 2. [The use of Cardioxan as a cardioprotective agent during antitumor chemotherapy].
    Lichinitser MR; Vyshinskaia GV; Min'kov ED; Nakhalova TA; Odzharova AA; Garin AM
    Ter Arkh; 1994; 66(7):54-6. PubMed ID: 7985130
    [No Abstract]   [Full Text] [Related]  

  • 3. New drug counters doxorubicin cardiotoxicity; not for use at start of chemotherapy.
    Am J Health Syst Pharm; 1995 Oct; 52(19):2076. PubMed ID: 8535936
    [No Abstract]   [Full Text] [Related]  

  • 4. Doxorubicin-induced cardiomyopathy.
    Swain SM
    N Engl J Med; 1999 Feb; 340(8):654; author reply 655. PubMed ID: 10049087
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
    Swain SM; Whaley FS; Gerber MC; Weisberg S; York M; Spicer D; Jones SE; Wadler S; Desai A; Vogel C; Speyer J; Mittelman A; Reddy S; Pendergrass K; Velez-Garcia E; Ewer MS; Bianchine JR; Gams RA
    J Clin Oncol; 1997 Apr; 15(4):1318-32. PubMed ID: 9193323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [An evaluation of the cardioprotective action of the preparation ICRF-187 (Cardioxane) during the treatment of breast cancer with large doses of adriamycin].
    Min'kov ED; Niu-Tian-de GB; Shkhvatsabaia LV; Bagdasarov IuB; Zaĭtseva TI; Odzharova AA
    Ter Arkh; 1994; 66(10):64-6. PubMed ID: 7863453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed administration of dexrazoxane provides cardioprotection against anthracyclines in breast cancer or acute myeloid leukemia.
    Lemez P
    J Clin Oncol; 1997 Oct; 15(10):3293-5. PubMed ID: 9336370
    [No Abstract]   [Full Text] [Related]  

  • 8. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
    Swain SM; Whaley FS; Gerber MC; Ewer MS; Bianchine JR; Gams RA
    J Clin Oncol; 1997 Apr; 15(4):1333-40. PubMed ID: 9193324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical status and optimal use of the cardioprotectant, dexrazoxane.
    Blum RH
    Oncology (Williston Park); 1997 Nov; 11(11):1669-77; discussion 1677-8, 1681. PubMed ID: 9394365
    [No Abstract]   [Full Text] [Related]  

  • 10. [The use of Cardioxane in chemotherapy of malignant neoplasms in children].
    Safonova SA; Punanov IuA; Dedukh VM; Kolygin BA
    Vopr Onkol; 1997; 43(4):459-61. PubMed ID: 9381706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin-induced cardiomyopathy.
    Muggia FM; Speyer JL
    N Engl J Med; 1999 Feb; 340(8):654-5. PubMed ID: 10049088
    [No Abstract]   [Full Text] [Related]  

  • 12. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
    Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
    Feola M; Garrone O; Occelli M; Francini A; Biggi A; Visconti G; Albrile F; Bobbio M; Merlano M
    Int J Cardiol; 2011 Apr; 148(2):194-8. PubMed ID: 19945181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of cardioxane (ICRF-187) in the prevention of cardiotoxicity of anthracyclines in the combined drug therapy of extensive ovarian cancer].
    Protasov DA; Zel'dovich DR; Kuz'mina LP; Manikhas GM
    Vopr Onkol; 1998; 44(6):718-21. PubMed ID: 10087973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation.
    Tonkin K; Bates M; Lieu D; Arundell E; Williamson T; Zagari M
    Can J Oncol; 1996 Nov; 6(2):458-73. PubMed ID: 12056098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of minoxidil in chemotherapy-induced alopecia.
    Duvic M; Lemak NA; Valero V; Hymes SR; Farmer KL; Hortobagyi GN; Trancik RJ; Bandstra BA; Compton LD
    J Am Acad Dermatol; 1996 Jul; 35(1):74-8. PubMed ID: 8682968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Reye syndrome in a child having received chemotherapy].
    Dubern B; Alessandri JL; Montbrun A; Attali T; Pilorget H; Samperiz S
    Arch Pediatr; 1998 Mar; 5(3):342-3. PubMed ID: 10328010
    [No Abstract]   [Full Text] [Related]  

  • 19. Amelioration of doxorubicin cardiotoxicity by the bispiperazinedione ICRF-187 in women with advanced breast cancer: a preliminary report.
    Jurga L; Misurová E; Vancík J
    Neoplasma; 1993; 40(4):259-62. PubMed ID: 8272153
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen.
    Jelić S; Radulović S; Nesković-Konstantinović Z; Kreacić M; Ristović Z; Bosnjak S; Milanović N; Vuletić L
    Support Care Cancer; 1995 May; 3(3):176-82. PubMed ID: 7655778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.